Research progress of nanocarrier-based drug delivery systems in the treatment of atherosclerosis
- VernacularTitle:纳米载体药物递送系统在动脉粥样硬化治疗中的研究进展
- Author:
Xiying HE
1
;
Jingjing WEI
2
;
Teng MA
3
;
Fan SU
1
;
Hongmei ZHENG
1
;
Xiaoman LI
1
;
Xiaomei WANG
4
Author Information
1. Dept. of Cardiology，Zhengzhou Yihe Hospital，Zhengzhou 450000，China
2. Dept. of Cardiology，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450003，China
3. Dept. of Integrated Traditional Chinese and Western Medicine，The First Affiliated Hospital of Zhengzhou University，Zhengzhou 450040，China
4. Dept. of Geriatrics，The First Affiliated Hospital of Jinzhou Medical University，Liaoning Jinzhou 121001，China
- Publication Type:Journal Article
- Keywords:
Atherosclerosis;
nanocarrier-based drug delivery systems;
biomimetic nanocarriers;
plaque microenvironment;
clinical translation
- From:
China Pharmacy
2026;37(20):2759-2764
- CountryChina
- Language:Chinese
-
Abstract:
Nanocarrier-based drug delivery systems can provide new research strategies for targeted intervention at atherosclerosis （AS） lesions by regulating the in vivo distribution and release behavior of drugs. Existing studies have shown that polymeric and lipid nanocarriers， cell membrane-coated systems， and microenvironment-responsive drug delivery strategies can intervene in the pathological progression of AS by modulating macrophage function， promoting cholesterol efflux， and controlling inflammation and oxidative stress； some systems have attempted to achieve multi-target synergistic intervention through combined delivery and theranostics； some drug delivery systems can improve drug enrichment in lesions and modulate related pathological processes. However， their long-term safety， lesion-targeting stability， scale-up manufacturing， and incremental clinical benefit remain to be validated. In the future， it is necessary to strengthen the matching between delivery mechanisms and pathological features and to establish evaluation systems for pharmacokinetics and safety， thereby providing a basis for the clinical translation of nanocarrier-based drug delivery systems.
